Ridgeback Biotherapeutics had no laboratories, no manufacturing facility of its own and a minimal track record when it struck a deal in March with Emory University to license an experimental coronavirus pill invented by university researchers with $16 million in grants from U.S. taxpayers.

Stocks flashed green around the world as investors clung to early reports that an antiviral medicine appeared to successfully treat severe symptoms for coronavirus patients.